Table 5.
Key Stage 2 and 3 Test Scores by APOE Genotype
| Key Stage 2 |
Key Stage 3 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | Coeffa | 95% CI | pb | n | Coeffa | 95% CI | pb | |||
| English | n = 5245 | n = 4487 | ||||||||
| ε2/ε2 | 46 | 3.26 | (−1.22, 7.74) | ε2/ε2 | 42 | 3.33 | (−1.85, 8.50) | |||
| ε2/ε3 | 704 | −.76 | (−2.02, .51) | ε2/ε3 | 618 | .51 | (−.98, 2.00) | |||
| ε2/ε4 | 141 | −.39 | (−2.98, 2.21) | ε2/ε4 | 122 | .74 | (−2.35, 3.82) | |||
| ε3/ε3 | 3019 | — | — | ε3/ε3 | 2566 | — | — | |||
| ε3/ε4 | 1218 | −.64 | (−1.66, .38) | ε3/ε4 | 1036 | .06 | (−1.16, 1.29) | |||
| ε4/ε4 | 117 | −.38 | (−3.22, 2.46) | .45 | ε4/ε4 | 103 | .32 | (−3.02, 3.67) | .83 | |
| Math | n = 5263 | n = 4607 | ||||||||
| ε2/ε2 | 45 | 3.79 | (−2.29, 9.87) | ε2/ε2 | 43 | 1.27 | (−5.20, 7.73) | |||
| ε2/ε3 | 709 | −.59 | (−2.28, 1.10) | ε2/ε3 | 632 | −1.38 | (−3.25, .48) | |||
| ε2/ε4 | 140 | −1.06 | (−4.56, 2.44) | ε2/ε4 | 125 | −.99 | (−4.84, 2.87) | |||
| ε3/ε3 | 3031 | — | — | ε3/ε3 | 2644 | — | — | |||
| ε3/ε4 | 1222 | −.78 | (−2.15, .59) | ε3/ε4 | 1054 | .22 | (−1.31, 1.75) | |||
| ε4/ε4 | 116 | −2.02 | (−5.85, 1.81) | .52 | ε4/ε4 | 109 | −.13 | (−4.24, 3.98) | .72 | |
| Science | n = 5310 | n = 4635 | ||||||||
| ε2/ε2 | 44 | 3.32 | (−.22, 6.86) | ε2/ε2 | 43 | −2.86 | (−10.05, 4.34) | |||
| ε2/ε3 | 713 | −.47 | (−1.43, .50) | ε2/ε3 | 633 | .98 | (−1.10, 3.05) | |||
| ε2/ε4 | 141 | .04 | (−1.97, 2.05) | ε2/ε4 | 127 | .89 | (−3.37, 5.14) | |||
| ε3/ε3 | 3067 | — | — | ε3/ε3 | 2661 | — | — | |||
| ε3/ε4 | 1228 | −.52 | (−1.30, .27) | ε3/ε4 | 1063 | 1.31 | (−.39, 3.01) | |||
| ε4/ε4 | 117 | .46 | (−1.73, 2.65) | .28 | ε4/ε4 | 108 | 2.89 | (−1.70, 7.49) | .46 | |
APOE, apolipoprotein E; CI, confidence interval.
a
From linear regression adjusted for gender and age at testing in months.
b
The p values for heterogeneity from analysis of covariance model.